- CX-516
drugbox
IUPAC_name = 6-(piperidin-1-ylcarbonyl)quinoxaline
PAGENAME.png
CAS_number = 154235-83-3
synonyms = Ampalex, CX-516
ATC_prefix =
ATC_suffix =
PubChem = 148184
DrugBank =
C = 14 | H = 15 | N = 3 | O = 1
molecular_weight = 241.289 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life = 45 minutes
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status = Investigational New Medicine
routes_of_administration =CX-516 is an
ampakine compound that works as an AMPA modulator and is being developed by a collaboration of Cortex and Shire and Servier. It was researched as a treatment forAlzheimer's disease, under the brand name Ampalex, and was also being examined as a treatment forADHD .CX-516 was the first ampakine compound developed by Cortex and while it showed good "in vitro" activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. However CX-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such as
farampator andCX-717 are compared to.References
* [http://nootropics.com/ampakines/cx516.html CX-516 therapy in Alzheimer's disease, schizophrenia and mild cognitive impairment]
ee also
*
AMPA
*Arecoline
*CX717
*Desmopressin
*Idebenone
*Vasopressin
*Vinpocetine
Wikimedia Foundation. 2010.
